Congescor 1.25 mg and 2.5 mg
Last Updated on eMC 06-May-2015 View document | Merck Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 06-May-2015 and displayed until Current
Reasons for adding or updating:
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 4.8 - Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
Date of revision of text on the SPC: 29-Apr-2015
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
The main change is the removal of the contra-indication in severe chronic obstructive pulmonary disease, which is moved to the Warnings section. There are also editorial changes in other sections, including QRD version 9 updates, such as how to report side effects in section 4.8.
Our Ref: TW778824.
Updated on 02-Feb-2015 and displayed until 06-May-2015
Reasons for adding or updating:
- New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Legal Category:POM
Black Triangle (CHM): NO
Merck
Merck Serono Ltd, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, UK
+44 (0)208 818 7267
+44 (0)208 818 7200
+44 (0)208 818 7373
+44 (0)208 818 7274
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue